• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

SimonMed Imaging Launches AI-Powered Personalized Breast Cancer Detection Program

by Jasmine Pennic 01/21/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– SimonMed Imaging, a provider of outpatient medical imaging services in the United States, today announced the nationwide launch of its AI-enabled Personalized Breast Cancer Detection (PBCD) program. 

– The program offers women a more comprehensive and personalized approach to breast cancer screening, empowering them to make informed decisions about their health.

PBCD Program Costs

For a cost of $40, patients can add the PBCD program to their screening 3D AI-enhanced mammogram. The program provides a personalized risk assessment, detailed breast density recommendations, and a tailored action plan outlining screening frequency and supplemental exams. This valuable information helps patients and their physicians make proactive decisions about breast health management.

The PBCD program offers several key benefits to patients:

  • Faster results: AI algorithms help expedite the analysis of mammograms, providing patients with quicker results and reducing anxiety.
  • Personalized risk assessment: The program analyzes individual risk factors to provide a personalized breast cancer risk score.
  • Detailed breast density recommendations: Provides information about breast density, a key factor in breast cancer risk.
  • Tailored action plan: Outlines personalized recommendations for screening frequency and supplemental exams, such as breast MRI or ultrasound.

 “SimonMed has offered AI technology in all 3D Mammograms to enhance breast cancer detection since 2019. Unlike other imaging centers, we offer this service at no additional cost to patients and will continue to do so,” said Dr. John Simon, CEO and Founder of SimonMed. “With PBCD, we’re taking AI enhanced Mammogram screening a step further by offering patients the option to have a timely, personalized risk assessment that considers each patient’s unique health profile. This comprehensive approach ensures that patients receive tailored recommendations for further screening, empowering them with the right care including ultrasound or MRI based on their individual risk levels. We know adding ultrasound or MRI to AI enhanced mammography with an individualized approach can more than double early detection. Our AI-driven platform is designed to help patients, and their healthcare providers, make more informed decisions, enhancing early detection and improving outcomes.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Breast Cancer, Medical Imaging Cloud, radiology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |